Tempus’ spectacular innovations in “precision medicine” would never have occurred if not for Eric Lefkofsky’s entrepreneurial spirit and desire to help those with cancer. Born in September 1969 and a native of Southfield, Michigan, Eric graduated from the University of Michigan with high honors in 1991 and then only two years later graduated from the same prestigious university with a Juris Doctorate degree. Eric then went on to spend much of his adult life in Chicago working as an entrepreneur and innovator in the rapidly expanding technology industry.
A diagnosis of cancer is one of the most devastating tragedies that can befall an individual and his family. Eric’s mission in life changed drastically when his wife was diagnosed with Breast Cancer. Rather than taking a passive role in his wife’s treatment and care and giving in to hopelessness and confusion, Eric felt “compelled to start a company” that is building a molecular clinical library as oncologists around the country send their patients to Tempus for genetic sequencing, clinical correlation and the best in treatment recommendations.
Traditionally, the main treatment available for cancer has been chemotherapy with all its dangers and side effects. Now, thanks to innovative companies like “Tempus”, co-founded by Eric Lefkofsky in 2016, new techniques utilizing the patient’s own genetic code and medical history are transforming cancer treatment.
Tempus has developed a software platform which can analyze a patient’s clinical data and pair this with his molecular data to more accurately determine the most effective cancer treatment currently available. Prior to this innovation, it was exceedingly difficult to glean and interpret much of the information and data in a patient’s medical record, but this new software now allows for natural language to be processed and optical character recognition to proceed to capture this crucial patient information in real time and learn more about Eric.
In this way, patient information is continually updated and coordinated with the patient’s sequenced genome. Targeted cancer therapy can then proceed using “precision medicine” whereby a patient’s genetic profile is used to determine specific targets on cancer cells and various proteins appropriate for treatment with a molecularly targeted drug and more information click here.
More Visit: http://lefkofskyfoundation.com/